323 related articles for article (PubMed ID: 27923592)
1. Developments in targeted therapy in melanoma.
Amann VC; Ramelyte E; Thurneysen S; Pitocco R; Bentele-Jaberg N; Goldinger SM; Dummer R; Mangana J
Eur J Surg Oncol; 2017 Mar; 43(3):581-593. PubMed ID: 27923592
[TBL] [Abstract][Full Text] [Related]
2. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
6. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
7. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
10. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
12. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
13. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Jang S; Atkins MB
Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
15. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
18. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in melanoma.
Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
[TBL] [Abstract][Full Text] [Related]
20. [Systemic treatment of inoperable metastasized malignant melanoma].
Gutzmer R; Rauschenberg R; Meier F
Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
